The evaluation of exosomal miRNA biomarkers for cachexia
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA915348 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR22878603.fastq.gz | Fastqsanger.gz | |||
| SRR22878604.fastq.gz | Fastqsanger.gz | |||
| SRR22878605.fastq.gz | Fastqsanger.gz | |||
| SRR22878606.fastq.gz | Fastqsanger.gz | |||
| SRR22878607.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 5 |
Similar Datasets
Project description:In order to screen miRNAs related to cachexia, we collected plasma from patients with gastric cancer cachexia or without cachexia, and extracted exosomes from plasma. Then, we analyzed the gene expression profile of 3 gastric cancer patients with cachexia and 2 gastric cancer patients with non cachexia.
2024-12-23 | GSE221666 | GEO
Project description:We identified exosomal miRNA biomarkers for pancreatic cancer diagnostics by isolating exosomes using a recently developed magnetic nanopore isolation technology and small RNA sequencing.
2019-02-11 | GSE111750 | GEO
Project description:Exosomal miRNAs have emerged as promising disease biomarkers. We aim to investigate the potential of exosomal miRNAs to assist with AIS clinical diagnosis. In the present research, we used the Affymetrix Genechip miRNA 4.0 Array to investgate the profiles of differentially expressed miRNAs (DEMs) in the exosomes of peripheral blood plasma. As a result, exosomal miRNA profiling yielded a total of 05 DEMs between the AIS (Acute Ischemic Stroke) patients and controls.
2025-03-10 | GSE291442 | GEO
Project description:Tuberculosis (TB) is difficult to diagnose under complex clinical conditions. Exosomal miRNAs have emerged as promising disease biomarkers. We aim to investigate the potential of exosomal miRNAs to assist with TB clinical diagnosis. In the present research, we used the Affymetrix Genechip miRNA 4.0 Array to investgate the profiles of differentially expressed miRNAs (DEMs) in the exosomes of peripheral blood plasma. As a result, exosomal miRNA profiling yielded a total of 102 DEMs (98 with up-expression and 4 with down-expression) between the TB (pulmonary tuberculosis and tuberculosis meningitis) patients and controls.
2018-07-03 | GSE116542 | GEO
Project description:Objective:This study aims to discover circulating exosomal miRNAs as potential noninvasive biomarkers early detection of fetus with ventricular septal defect (VSD). Method:A total of 182 pregnant women including 91 VSD cases and 91 matched controls were included in this study. Exosomes were isolated and next-generation sequencing was used to obtain a profile of dysregulated exosomal miRNA. The differential abundance was verified by quantitative real-time PCR (q RT-PCR). . Receiver operating characteristic (ROC) curves were conducted to evaluate the diagnostic accucary Results: 77 serum exosomal miRNA were uncovered to be differentially expressed in the VSD group as compared to the control group. Among these, five down-regulated exosomal miRNA were validated by qRT-PCR. hsa-miR-146a-5p was identified to be capable of distinguishing VSDs from controls (area under the ROC (AUC): 0.997; p < 2.2e-16). Conclusion: circulating exosomal miRNA, in particular, hsa-miR-146a-5pmay be a predictive biomarker for non-invasive prenatal diagnosis of fetal VSDs.
2021-06-05 | GSE176134 | GEO
Project description:Preeclampsia is a common complication of pregnancy that affects 4-5% of pregnant women around the world. At present, there is a lack of early identification of high-risk patients of preeclampsia in clinical practice, which restricts the development of disease prevention and treatment. Previous studies have indicated that plasma exosomal miRNAs in pregnant women could serve as biomarkers of preeclampsia, but few is focused on exosomal miRNAs from preeclampsia pregnancy with severe features(sPE). Therefore, we detected and compared the plasma exosomal miRNA profiles between normal pregancy and sPE to explore potential biomarkers and pathogenic mechanisms of sPE.
2021-11-30 | GSE175807 | GEO
Project description:Over 80% of patients with pancreatic ductal adenocarcinoma (PDAC) suffer from cachexia, characterized by severe muscle and fat loss and yet, there are no biomarkers identified for this debilitating condition. Our objective was to identify circulating protein biomarkers using serum for human PDAC cachexia and understand their biological functions. Serum from 30 patients with PDAC was collected and protein profiles were generated using SOMAscan. The protein profiles were correlated with clinical variables such as Cancer associated weight loss (CAWL), body composition measurements of skeletal muscle index (SMI), skeletal muscle density (SMD), total adipose index (TAI) using Spearman’s correlation. Overall, 110 proteins of 1294 correlated with these clinical measures - 47 proteins for CAWL, 19 for SMI, 14 for SMD, and 30 for TAI (r-value 0.5, p<0.05). LYVE1, a homolog of CD44 implicated in tumor metastasis, was the top CAWL-associated protein (r= 0.67, p=0.0001). Protein co-expression network analysis identified immune system related pathways such as B-cell signaling, natural killer cell signaling, IL6 signaling in addition to identifying other known pathways in cachexia. Taken together, these data identify both immune system molecules and additional secreted factors and pathways not previously associated with PDAC and confirm the activation of previously identified pathways.
2020-12-31 | GSE119483 | GEO
Project description:We aimed to identify urinary exosomal ncRNAs as novel biomarkers for diagnosis of Chronic Kidney Disease (CKD) for this, we examined 15 exosomal ncRNA profiles in urine samples from CKD patients from four different stages (I, II, III and IV) and compared them to 10 healthy controls. We identified a significant number of novel, differentially expressed ncRNAs in CKD patients compared to healthy, which might be employed as early diagnostic markers in CKD in the future.
2016-11-30 | E-MTAB-5152 | biostudies-arrayexpress
Project description:Chronic myeloid leukemia (CML) is a stem cell-derived malignancy driven by the BCR-ABL oncogene. Imatinib (IM) is a targeted therapy used to treat CML; however, primary resistance and molecular evidence of persistent disease have been observed in some patients. Recent evidence suggests that exosome-derived microRNAs (miRNAs) contribute to drug resistance and may serve as novel biomarkers for cancer diagnosis and drug sensitivity prediction. This study aimed to explore the plasma exosomal miRNA profiles in patients with CML to identify biomarkers associated with IM resistance. Exosomes isolated from the plasma of patients with IM-sensitive and -resistant CML patients were characterized, and exosomal miRNA profiling was conducted using RNA sequencing. Differential expression analysis identified 13 upregulated miRNAs and 21 downregulated miRNAs. Bioinformatics analysis highlighted pathways related to autophagy and PI3K-Akt signaling. Among the upregulated miRNAs, miR-451 and miR-16 were significantly elevated in exosomes from IM-resistant patients compared with those from IM-sensitive patients. Target gene analysis of these miRNAs was performed. Our findings suggest that plasma exosomal miRNAs, particularly miR-451 and miR-16, can serve as potential biomarkers for IM resistance in CML. These results offer new insights into the molecular mechanisms underlying IM resistance and may inform future therapeutic strategies.
2025-03-03 | GSE290959 | GEO
Project description:The aim of this study was to identify and evaluate exosomal miRNAs in serum as early diagnostic markers for gastric cancer (GC). Methods: Using next-generation sequencing (NGS) and bioinformatics, we identified candidate serum exosomal miRNA markers for early detection of GC in patients. The candidates were further validated by qRT-PCR in 50 newly recruited early-stage GC patients and matched healthy individuals. Results: NGS revealed that the average mappable reads in the RNA libraries were about 6.5 million per patient. A total of 66 up and 13 down-regulated exosomal miRNAs were found in the screened cohort after removal of log2 transformed read counts <5 and p >0.05. In the validation cohort, by comparing candidate exosomal miRNAs levels in early-stage GC patients and healthy individuals, higher levels of miR-92b-3p, let-7g-5p, miR-146b-5p and miR-9-5p were found to be significantly associated with GC. Diagnostic power of the combined panels of the exosomal miRNAs or the combination of exosomal miRNAs and CEA outperformed that of single exosomal miRNA marker for establishing a diagnosis of early-stage GC. In addition, serum levels of exosomal miR-92b-3p were significantly associated with low adhesion, let-7g-5p and miR-146b-5p were significantly correlated with nerve infiltration, and miR146b-5p was statistically correlated with tumor invasion depth in early-stage GC. Conclusions: Serum exosomal miR-92b-3p, -146b-5p, -9-5p, and let-7g-5p may serve as potential noninvasive biomarkers for early diagnosis of GC. Further validation of these candidate exosomal miRNAs in larger experimental cohorts are required in order to confirm the diagnostic values.
2020-02-21 | GSE130654 | GEO